Foghorn Therapeutics Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Foghorn Therapeutics Inc. (FHTX) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 11.92 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-06
- Foghorn Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-03-31 was 11.92M shares, a 65.02% increase year-over-year.
- Foghorn Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-03-31 was 7.22M shares.
- Foghorn Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-03-31 was 0.00 shares.
- Foghorn Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2025 was 6.49M shares, a 10.05% decline from fiscal 2024.
- Foghorn Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 7.22M shares.
- Foghorn Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | 11.92M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 11.92M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 6.49M shares 10-K · filed 2026-03-11 | |||
| 2025-09-30 | 6.49M shares 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 7.22M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 7.22M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 7.22M shares 10-K · filed 2026-03-11 | |||
| 2024-09-30 | 7.22M shares 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 7.22M shares 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 0.00 shares 10-K · filed 2025-03-06 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |